MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Clinical trials for MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS explained in plain language.
Never miss a new study
Get alerted when new MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS trials appear
Sign up with your email to follow new studies for MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for kids with severe bowel disease: drug trial launches
Disease control Recruiting nowThis study tests a new medicine called afimkibart in children aged 2 to 17 with moderate to severe ulcerative colitis, a condition causing inflammation and sores in the colon. The goal is to see if the drug can safely reduce symptoms and help children reach remission (feeling bet…
Matched conditions: MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 26, 2026 12:03 UTC
-
New hope for ulcerative colitis patients in late-stage trial
Disease control Recruiting nowThis study tests a new medicine called RO7790121 (Afimkibart) in people with moderate-to-severe ulcerative colitis, a chronic bowel disease. About 350 adults will receive either the drug or a placebo for 12 weeks to see if it can reduce symptoms like diarrhea, bleeding, and infla…
Matched conditions: MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 19, 2026 11:48 UTC